Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
262.30B
Market cap262.30B
Price-Earnings ratio
17.24
Price-Earnings ratio17.24
Dividend yield
2.57%
Dividend yield2.57%
Average volume
1.68M
Average volume1.68M
High today
$125.72
High today$125.72
Low today
$123.24
Low today$123.24
Open price
$125.59
Open price$125.59
Volume
2.29M
Volume2.29M
52 Week high
$134.00
52 Week high$134.00
52 Week low
$96.06
52 Week low$96.06

Stock Snapshot

With a market cap of 262.3B, Novartis(NVS) trades at $125.56. The stock has a price-to-earnings ratio of 17.24 and currently yields dividends of 2.6%.

During the trading session on 2025-11-21, Novartis(NVS) shares reached a daily high of $125.72 and a low of $123.24. At a current price of $125.56, the stock is +1.9% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 2.29M, compared to an average daily volume of 1.68M.

Over the past 52 weeks, Novartis(NVS) stock has traded between a high of $134.00 and a low of $96.06.

Over the past 52 weeks, Novartis(NVS) stock has traded between a high of $134.00 and a low of $96.06.

NVS News

Benzinga 18h
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it b...

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
TipRanks 23h
Novartis sees +5%-6% sales CAGR cc for 2025-2030

Novartis (NVS) rolled forward its mid-term guidance to 2025-2030 with a sales CAGR of +5-6% cc. The updated outlook will be featured at its Meet Novartis Manage...

TipRanks 1d
Novartis AG: Hold Rating Amid Moderate Growth and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities reiterated a Hold rating on Novartis AG, retaining the price target of CHF111.00. TipRanks Black Friday Sale C...

Analyst ratings

57%

of 28 ratings
Buy
25%
Hold
57.1%
Sell
17.9%

More NVS News

The Wall Street Journal 1d
Novartis Expects Steady Sales Growth Through 2030

Novartis has raised its peak sales guidance for Kisqali for breast cancer and Scemblix for leukemia. Brian Snyder/Reuters Novartis NOVN 0.22 %increase; green u...

Novartis Expects Steady Sales Growth Through 2030
Nasdaq 1d
Novartis To Build Flagship Manufacturing Hub In North Carolina

(RTTNews) - Novartis (NVS) announced plans to expand its operations in North Carolina with the creation of a new flagship manufacturing hub featuring end-to-end...

Novartis To Build Flagship Manufacturing Hub In North Carolina
Seeking Alpha 2d
Novartis to establish a manufacturing center in North Carolina

Novartis (NVS) said it will grow its operations in North Carolina by establishing a new manufacturing hub that will handle the entire production process. This...

Novartis to establish a manufacturing center in North Carolina
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.